» Articles » PMID: 37670327

The Metabolomic Plasma Profile of Patients with Duchenne Muscular Dystrophy: Providing New Evidence for Its Pathogenesis

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2023 Sep 5
PMID 37670327
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Duchenne muscular dystrophy (DMD) is a fatal genetic muscle-wasting disease that affects 1 in 5000 male births with no current cure. Despite great progress has been made in the research of DMD, its underlying pathological mechanism based on the metabolomics is still worthy of further study. Therefore, it is necessary to gain a deeper understanding of the mechanisms or pathogenesis underlying DMD, which may reveal potential therapeutic targets and/or biomarkers.

Results: Plasma samples from 42 patients with DMD from a natural history study and 40 age-matched healthy volunteers were subjected to a liquid chromatography-mass spectrometry-based non-targeted metabolomics approach. Acquired metabolic data were evaluated by principal component analysis, partial least squares-discriminant analysis, and metabolic pathway analysis to explore distinctive metabolic patterns in patients with DMD. Differentially expressed metabolites were identified using publicly available and integrated databases. By comparing the DMD and healthy control groups, 25 differential metabolites were detected, including amino acids, unsaturated fatty acids, carnitine, lipids, and metabolites related to the gut microbiota. Correspondingly, linoleic acid metabolism, D-glutamine and D-glutamate metabolism, glycerophospholipid metabolism, and alanine, aspartate, and glutamate metabolism were significantly altered in patients with DMD, compared with those of healthy volunteers.

Conclusions: Our study demonstrated the abnormal metabolism of amino acids, energy, and lipids in patients with DMD, consistent with pathological features, such as recurrent muscle necrosis and regeneration, interstitial fibrosis, and fat replacement. Additionally, we found that metabolites of intestinal flora were disordered in DMD patients, providing support for treatment of intestinal microbia disturbance in DMD diseases. Our study provides a new research strategy for understanding the pathogenesis of DMD.

Citing Articles

Beta-hydroxy-beta-methylbutyrate (HMB) improves daily activity and whole-body protein metabolism in Duchenne muscular dystrophy dogs: a pilot study.

Nghiem P, Rutledge A, Tehas K, Kaderli C, Poling M, Arnim S Sci Rep. 2025; 15(1):4026.

PMID: 39894866 PMC: 11788438. DOI: 10.1038/s41598-025-88651-8.


Serum metabolomic signatures of patients with rare neurogenetic diseases: an insight into potential biomarkers and treatment targets.

Wijekoon N, Gonawala L, Ratnayake P, Sirisena D, Gunasekara H, Dissanayake A Front Mol Neurosci. 2025; 17:1482999.

PMID: 39866907 PMC: 11759312. DOI: 10.3389/fnmol.2024.1482999.


The Gut Microbiota Involvement in the Panorama of Muscular Dystrophy Pathogenesis.

Russo C, Surdo S, Valle M, Malaguarnera L Int J Mol Sci. 2024; 25(20).

PMID: 39457092 PMC: 11508360. DOI: 10.3390/ijms252011310.


Caveolin and NOS in the Development of Muscular Dystrophy.

Nakashima M, Suga N, Yoshikawa S, Matsuda S Int J Mol Sci. 2024; 25(16).

PMID: 39201459 PMC: 11354531. DOI: 10.3390/ijms25168771.


Characterization of disease-specific alterations in metabolites and effects of mesenchymal stromal cells on dystrophic muscles.

Nitahara-Kasahara Y, Posadas-Herrera G, Hirai K, Oda Y, Snagu-Miyamoto N, Yamanashi Y Front Cell Dev Biol. 2024; 12:1363541.

PMID: 38946797 PMC: 11211584. DOI: 10.3389/fcell.2024.1363541.


References
1.
Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G . Current Pharmacological Strategies for Duchenne Muscular Dystrophy. Front Cell Dev Biol. 2021; 9:689533. PMC: 8417245. DOI: 10.3389/fcell.2021.689533. View

2.
Berthillier G, Eichenberger D, Carrier H, GUIBAUD P, GOT R . Carnitine metabolism in early stages of Duchenne muscular dystrophy. Clin Chim Acta. 1982; 122(3):369-75. DOI: 10.1016/0009-8981(82)90140-1. View

3.
Jang C, Oh S, Wada S, Rowe G, Liu L, Chan M . A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med. 2016; 22(4):421-6. PMC: 4949205. DOI: 10.1038/nm.4057. View

4.
Hassanov T, Karunker I, Steinberg N, Erez A, Kolodkin-Gal I . Novel antibiofilm chemotherapies target nitrogen from glutamate and glutamine. Sci Rep. 2018; 8(1):7097. PMC: 5940852. DOI: 10.1038/s41598-018-25401-z. View

5.
Dubinin M, Talanov E, Tenkov K, Starinets V, Mikheeva I, Sharapov M . Duchenne muscular dystrophy is associated with the inhibition of calcium uniport in mitochondria and an increased sensitivity of the organelles to the calcium-induced permeability transition. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(5):165674. DOI: 10.1016/j.bbadis.2020.165674. View